

Japan Mission

October 9th to 14th 2016

Delegation Brochure

Your Gateway in Europe to Life Sciences and Healthcare



bioXclusters⁺
European Cluster Partnership
on Personalised Healthcare



This initiative is part of the project bioXclusters plus – the European Strategic Cluster Partnership (ESCP) on Personalised Healthcare which has received funding from the European Union's COSME Programme (2014-2020)



European Cluster Partnership on Personalized Healthcare

bioXclusters plus is the leading European meta-cluster on personalised healthcare, which has doubled the number of companies it represents over the last four years. It has brought together four of the most dynamic and fastest growing life science and healthcare clusters in Europe (Catalonia, Bavaria, Piemonte, and Auvergne-Rhône-Alpes) and offers the best gateway to finding your partner of choice.


bioXclusters plus represents 3,300 innovative, European SMEs focused on personalised healthcare (mainly in personalised medicine, oncology, cardiovascular, inflammatory, infectious diseases and the central nervous system), with a wide technological offer.

bioXclusters plus was selected by the European Commission in 2016 as the unique European Strategic Cluster Partnership on Personalised Healthcare. Its objectives are to offer an entry point for global players to Europe and build up gateways on strategic markets to foster international collaborations.

4 leading life sciences and healthcare clusters in Europe



Key data



Japan, a real strategic market for SMEs

bioXclusters plus has one single overarching aim: **to support the competitiveness of SMEs by facilitating internationalization and the creation of a single European entry point for global players in the life sciences and health sector.** It shares best practices with its extensive network of members, stimulating synergies and innovation, and offers key advice, information and a contact point for company entry into strategic, international markets. Japan is currently identified as one of the most attractive markets by European SMEs from the healthcare sector including: biotech, drug discovery, diagnostics, medtech and others. This is why the bioXclusters plus alliance is willing to offer SMEs opportunities to meet up new partners and build reliable gateways for these target markets.

Furthermore, **bioXclusters plus** has prioritized the following areas in healthcare for development and support: personalised medicine, regenerative therapies, digital health, which are trends mutually shared by the Japanese industrial players and authorities.

Key achievements of the initial bioXclusters project (2012-2014)

- 11 business agreements signed between international and European entities and SMEs for future partnerships.
- 6 MoUs signed (3 with Brazil, 2 with China and 1 with the USA) to support future business relationships.
- 202 European SMEs participated in bioXclusters' missions and/or attended international trade fairs, to promote contacts and to share know-how for future growth.
- 3 study trips, 1 EU matchmaking mission in Brazil and 3 European round-trips for invited experts.

Your Gateway in Europe to Life Sciences and Healthcare

Lyonbiopole, a French healthcare cluster fostering innovation in Auvergne-Rhône-Alpes, a vibrant territory in the heart of Europe.

Lyonbiopole is the gateway to healthcare innovation in Auvergne Rhône-Alpes Region. The cluster supports ambitious projects and companies in the health sector (including infectious diseases, cancer, nutrition, metabolic diseases). Its aim is to support innovative technologies, products and services for a more personalized medicine to the patient's benefit. Lyonbiopole is the cluster which coordinates bioXclusters plus.

The cluster's missions are: 1) promoting the emergence of innovative R&D collaborative projects; 2) supporting SMEs for strategic partnerships, access to private investors, expertise and training; 3) fostering SME internationalization and the cluster position at EU and an international level; 4) giving access to high-level, dedicated facilities. In 2015, Lyonbiopole represents a community of 190 members: 5 world-class leaders including Lyonbiopole's founders (Sanofi Pasteur, bioMérieux, Merial, BD) – 17 research centres including 3 hospital university centres and almost 168 SMEs. Lyonbiopole received the European cluster excellence "Gold Label" from ECEI in 2014.

Dr. Simon Gudin – SMEs' Development Project Manager
Simon.gudin@lyonbiopole.com

Bio^M Biotech Cluster Development GmbH is the coordinating agency of the Bavarian Biotech Cluster for all fields of biotechnology. Bio^M also coordinates the Munich Biotech Cluster with a focus on personalized medicine. It serves as the one-stop-shop for biotechnology companies and start-ups in the region as well as the first point of contact for international partners.

Bavaria is a constantly growing hotbed of innovation and ranks among the top biotech clusters in Europe. It has more than 350 companies in the life science sector (biotech, pharma, CRO, suppliers, additionally 1,000 companies belong to medical engineering), including 166 biotech SMEs and a well-filled drug development pipeline with more than 60 candidate drugs in clinical development and more than 80 candidates in the preclinic. Bio^M collaborates with other cluster organisations (e.g. medtech), life science incubators and research institutions in Bavaria to connect the Bavarian life science hotspots in one large state-wide network.

Bio^M offers a wide range of services and events, including networking and partnering services for incoming global players interested in business contacts in Bavaria. It also manages a comprehensive information portal with an interactive company database and a large job market.

Dr. Stephanie Wehnelt – Head of International Affairs & Training
wehnelt@bio-m.org

Baldiri Reixac, 4-8, Torre I (PCB)
08028 Barcelona
www.biocat.cat



Biocat coordinates and promotes the healthcare and life sciences sector in Catalonia. Its mission is to dynamise and support the public and private stakeholders that make up the BioRegion, Catalonia's bioscience cluster, which encompasses companies, research groups and bodies, hospitals, universities, administrations and knowledge- and innovation-transfer support structures.

With a population of more than 7.5 million and a territory comparable to that of European countries like Finland, Belgium, the Netherlands and Israel, Catalonia has the most dynamic life sciences cluster in Spain and one of the most active in southern Europe. Biocat promotes initiatives to encourage research, innovation and business growth, with the aim of making this sector a driving force for the Catalan economy and boosting its global recognition.

The BioRegion of Catalonia is made up of 734 healthcare and life sciences companies and 89 research bodies, including 41 research centers, 15 university hospitals, 13 science and technology parks, 11 universities offering biosciences degrees, 7 technology centers and 2 large-scale facilities like the Alba-Cells Synchrotron and the Barcelona Supercomputing Center (BSC). The companies in the sector post yearly turnover of €14.36 billions, 7% of the GDP of Catalonia and employ 42,133 workers.

Albert Barberà – CEO
abarbera@biocat.cat
Jordi Fàbrega – Director of Business Development
jfabrega@biocat.cat

Via Ribes 5
10010 Colleretto Giacosa (To) – Italy
www.biopmed.eu



bioPmed is the cluster for life sciences and human health for the Piedmont Region of Italy. bioPmed is the result of the formal aggregation of about 70 players, ranging from large multinational corporations to hi-tech start-ups and innovative SMEs, and including universities and research foundations. They all work together and share a solid strategic plan to create innovation and development in the field of health. BioPmed and the core partner are the key component of a community of over 350 companies, than makes bioPmed one of the strongest regional health cluster in Italy based on the value of collaboration. BioPmed activities in the period 2016-2020 are based on four strategic operational priorities: innovation, internationalisation, business development and positioning. Technological focus of bioPmed activities is based on the deployment of solutions, products, services and processes following the "4ps" approach (prevention, prediction, personalisation, participation).

bioPmed is managed by Bioindustry Park Silvano Fumero SpA (www.bioindustrypark.eu), which in 2015 obtained the GOLD LABEL Certification of Excellence in Cluster Management from ESCA, the European Secretariat for Cluster Analysis: the only one awarded in Italy in the health sector and part of a restricted group of less than 10 throughout Europe.

Alberto Baldi – Cluster Manager
baldi@bioindustrypark.it

List of companies in the **bioXclusters plus** delegation :

2bind GmbH

4SC AG

Ability Pharmaceuticals S.L.

Apceth GmbH & Co. KG

Ascenion GmbH

Bioindustry Park Silvano Fumero SpA

Boeters & Lieck

Coriolis Pharma Research GmbH

CTIBiotech

CYTOO SA

FGK Clinical Research GmbH

Gams Wellness

genOway

Indicia Production

Iris Biotech GmbH

Klifovet AG

Laboratorios Rubió S.A.

Laboratorios Salvat S.A.

Leukocare AG

Leukos Biotech

Medigene AG

Mind the Byte S.L.

Novotec

Theranexus

Thrombotargets Europe S.L.

Zeclinics S.L.

2BIND GMBH
Am BioPark 13
BioPark III
93053 Regensburg - Germany
www.2-bind.com

MAIN CONTACT:
Dr. Thomas Schubert
CEO
Schubert@2bind.de
Phone: +49 (0) 160 96938061

The 2-bind GmbH is a service provider for molecular interaction analyses based on the patented and powerful 'Microscale Thermophoresis' technology of Nano Temper. This new technology detects changes in the hydration shell of molecules in solution and is the ideal assay for measuring biomolecule interactions and for determination of dissociation constants. Applications range from the analysis of molecular interactions to enzymatic assays.

Advantages of Microscale Thermophoresis:

- Measurement in solution without surface immobilisation
- Free choice of reaction conditions
- Small reaction volumes (3 µl) with low material requirement
- Fast measurements in a dynamic range (nM-mM)
- Interactions between very small and very large molecules can be determined

4SC AG
Am Klopferspitz 19a
82152 Planegg-Martinsried - Germany
www.4sc.com

MAIN CONTACT:
Mr. Rolf Krauss
Alliance Management
rolf.krauss@4sc.com
Phone: +49 89 700763-0
Cell phone: +49 176 170079-94

4SC is a biotech company dedicated to the clinical development of small molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options for cancer patients that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy.

In order to broaden its expertise in the field of epigenetics and immunology, 4SC is seeking for academic and commercial collaborations in this field. 4SC is in particular interested in:

- Epigenetic regulation of immune signaling
- Influencing the tumor microenvironment
- Combination concepts for epigenetic drugs (Resminostat and 4SC-202) with other therapeutics in the field of cancer

ABILITY PHARMA SL
Edifici Eureka, Campus de la UAB
08193 Bellaterra - Barcelona
www.abilitypharma.com

MAIN CONTACT:
Mr. Carles Domenech
CEO
carles.domenech@gmail.com
Phone: +34 606 433 824
Cell phone: +34 606 433 824

AbilityPharma is a cancer therapeutics company developing a new drug class. Our first candidate ABTL0812, oral targeted therapy, has successfully finished phase 1/1b clinical trials, with phase 2a clinical trials starting in September 2016 in lung and endometrial cancer. It will also be developed in pancreatic and breast cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma.

In April 2016, AbilityPharma signed a license agreement with the US company SciClone for China, Taiwan and Vietnam. The current priority of the company is to license it for Japan in the first half of 2017.

ABTL0812 is a fully differentiated inhibitor of the PI3K/Akt/mTOR (PAM) pathway, a validated anti-cancer target attractive for development by big and mid-size pharma companies. The MoA has been published at Clinical Cancer Research in May 2016. It inhibits the PAM pathway through the overexpression of the endogenous Akt inhibitor TRIB3.

ABTL0812 has the best safety and tolerability, extremely low toxicity and better efficacy on biomarkers than most PAM inhibitors, with several responses in the phase 1 clinical trial. It is efficacious as single agent and potentiates chemotherapy without increasing toxicity. It is efficacious in resistant cells, it inhibits metastasis formation and is active on tumor stem cells.

APCETH GMBH & CO. KG
Haidgraben 5
85521 Ottobrunn - Germany
www.apceth.com

MAIN CONTACT:
Dr. Christine Günther - CEO
c.guenther@apceth.com
Phone: +49 (0)89 7009 608-0

apceth - TWO PILLARS OF THE BUSINESS MODEL

PROPRIETARY TECHNOLOGY & PRODUCTS

- Clinical stage biopharmaceutical company
- Global leader in the development of cell-based gene therapies
- Genetically engineered and native mesenchymal stem cell therapeutics
- Cancer, immunomodulation, chronic lung and kidney diseases

CONTRACT DEVELOPMENT & MANUFACTURING ORGANISATION (CDMO)

- Reliable, experienced and high-performance partner for our clients
- Complex cell-based and gene therapy products (ATMPs)
- Product, process and assay development
- Clinical and commercial GMP manufacturing
- GMP-certified since 2010

apceth's proprietary platform technology is based on next generation genetically engineered mesenchymal stem cells (MSC). With a huge potential as an effective therapy with almost no side effects, it could circumvent the limitations and risks of standard therapies for cancer and severe diseases. MSC migrate inherently to tumors and areas of tissue damage and inflammation in the body. apceth's engineered MSC can combine any therapeutic gene, chosen to counteract the specific mechanisms of a target disease, with any tissue- or disease-specific gene promoter. The versatility of apceth's MSC platform provides an ideal tool-box for the design of targeted cell therapy approaches for a variety of medical conditions.

apceth is the first company worldwide to advance genetically engineered MSC for cancer therapy into clinical testing. Our first-in-men / first-in-class phase I/II clinical trial in advanced gastrointestinal cancers will complete the phase II in 2016 (TREAT-ME 1, NCT02008539). The company was founded in 2007. It is owned by the investors and the scientific founders.



ASCENION GMBH
Herzogstrasse 64
80803 Munich - Germany
www.ascenion.de

MAIN CONTACT:
Ms. Esther Lange
Industry Liaison Manager
lange@ascenion.de
Phone: +49/89/318814-22

Ascenion is the exclusive technology transfer partner to numerous research institutes of the Helmholtz and Leibniz Associations, the Hannover Medical School and associated organizations for translational research. Our focus is on the life sciences.

We advise public life-science research institutions in all aspects of intellectual property asset management. With our support, commercially attractive inventions, materials and know-how are promptly identified and given appropriate patent protection. We find suitable industrial partners, negotiate licensing and cooperation agreements, and accompany start-ups on the road to independence. Ideas thereby lead to new jobs and products, such as a novel anti-cancer drug or a procedure for identifying harmful bacteria in drinking water. The proceeds from commercialization flow back to the research institutions.

Ascenion is the exclusive partner of 25 life-science institutes in the Helmholtz and Leibniz Associations and the Medical School Hanover. Furthermore we are presenting selected projects from the Charité in Berlin. We currently market around 700 patent families, together with a varied range of research materials, e.g. antibodies, animal models and vectors.



BIOINDUSTRY PARK SILVANO FUMERO
Via Ribes, 5
10010 Colletterto Giacosa (TO) - Italy
www.bioindustryPark.eu

MAIN CONTACT:
Fabrizio Conicella
conicella@bioindustryPark.it
Phone: +390125561311

Bioindustry Park Silvano Fumero SpA is a Science & Technology Park located in Piemonte region, in the north-west of Italy. The Park is a limited company with public majority, with the mission of promoting and developing research in Life Sciences. Hosting companies of the chemical, pharmaceutical, diagnostic, bioengineering and information science fields. Bioindustry Park has 3 major services platforms available for companies and research centers:

- Able Bioscience is the scientific division of Bioindustry Park Silvano Fumero responsible for scientific services of research and development for Biotech, Pharmaceutical and Biomedical companies.
- FORlab is the Custom Organic Synthesis department of Bioindustry Park. As scientific service provider focused on Organic Chemistry, FORlab delivers solutions and products for Chemical, Pharmaceutical and Biotech industries.
- Ex2O Expert in Exploit Opportunities" (EX2O) is the specialistic service platform that offers services of: Technology transfer and Technology evaluation and business plan development and valuation, Strategic advice, Business development advice, Science park and incubator management advice and cluster development advice, Innovation management and technology transfer training.

BOETERS & LIECK
Oberanger 32
80331 Munich - Germany
www.Boeters-Lieck.de

MAIN CONTACT:
Mr. Dietmar Forstmeyer
Partner
info@boeters-lieck.eu
Phone: +49 89 23 23 65 90

BOETERS & LIECK is an intellectual property law firm with roots dating back to 1968. The firm is located in Munich in proximity to the seat of the European Patent Office and the German Patent and Trademark Office.

Boeters & Lieck provides all services related to intellectual property including patents, utility models, designs, trademarks and plant varieties in German and Europe. Attorneys at law specialized in IP allow us to offer qualified services in nullity and infringement proceedings, unfair competition and antitrust law and licensing matters.

CORIOLIS PHARMA RESEARCH GMBH
Am Klopferspitz 19
82152 Martinsried - Germany
www.coriolis-pharma.com

MAIN CONTACT:
Dr. Michael Wiggenhorn - CEO
Michael.wiggenhorn@coriolispharma.com
Phone: +49 89 542449810
Mobile: +49 151 20121093

Coriolis Pharma is a world leading independent contract research organization for BIOPHARMACEUTICAL FORMULATION and DRUG PRODUCT DEVELOPMENT including, LYOPHILIZATION PROCESS and ANALYTICAL DEVELOPMENT such as proteins, peptides, monoclonal antibodies, RNA/DNA etc., and vaccines. This contains high concentrated protein formulations or developments for subcutaneous administrations or other complex formulations.

This is complemented by outstanding capabilities and know-how in the fields of protein characterization (higher order structure characterization, aggregation, subvisible particles, surfactant characterization, etc.). Coriolis Pharma is expert in the latest innovative analytical technologies (e.g. analytical ultracentrifugation with SEDFIT and also UltraScan, Archimedes, quantitative Far- and Near-UV CD).

In addition to that we also offer as standalone services GMP compliant analytics for SUBVISIBLE PARTICLE ANALYSIS and AGGREGATION CHARACTERIZATION (e.g. Light obscuration (LO), Flow Imaging spectroscopy (MFI), Asymmetrical flow field-flow fractionation (AF4), Resonant mass measurement (RMM), Nano particle tracking (NTA), Dynamic light scattering (DLS), Turbidity, Semi automated visual inspection (ETAC)).



CTI BIOTECH

**Bata. 16, 5 Avenue Lionel Terray
69330 Meyzieu-Lyon - France
www.ctibiotech.com**

MAIN CONTACTS:

**Dr. Nico Forraz / CEO
Professor Colin McGuckin / CSO
office@ctibiotech.com
Phone: +33 967 10 74 55
Cell phone: +33 6 78 90 38 50**

CTIBIOTECH's mission is to maximize the potential of tissues created by stem cell technologies and cancer biopsies for human therapeutic benefit.

CTIBIOTECH specializes in biotechnologies and particularly in research on cancer, stem cells, tissue engineering and the production of innovative cell models (in vitro et ex vivo) for biomedical, pharmaceutical and dermatocosmetic research, as well as medical devices applied to cell therapy.

CTIBIOTECH contributes to the development of new cell and regenerative therapies in order to make progress in the treatment of diseases such as cerebral palsy, strokes, diabetes, cancer, orthopedic and cranio-facial malformations, blood diseases as well as immune system, kidney, hepatic and cardiovascular diseases.

CTIBIOTECH develops innovative human 2D and 3D skin models for dermatology and cosmetics research including sebocytes, hair follicle models, immunity skin models, sensitive skin models ,etc.

CTIBIOTECH develops innovative human 2D and 3D in vitro cancer models to accelerate therapeutic innovation and identification of anticancer therapies, with a rapid transfer to the clinic, to the direct benefit of patients.

CYTOO SA

**Minatec - BHT - Bât. 52
7 parvis Louis Néel
38040 Grenoble cedex 9 - France
www.cytoo.com**

MAIN CONTACT:

**Mr. Mathieu Raul
Business Development Director
mraul@cytoo.com
Phone: +33 426 78 39 63
Cell phone: +33 7 86 63 99 53**

CYTOO is a preclinical stage Contract Research Organization focused on the development and commercialization of innovative cell-based assays derived from first-in-class skin and muscle tissue models.

CYTOO's proprietary physiological and HCS compatible assays address the following markets:

- Skeletal Muscle: pharmaceutical and biotechnology (sarcopenia, diabetic muscle, rare genetic diseases including but not limited to DMD), animal health and nutraceutical;
- Skin: cosmetology (skin care, skin firmness, anti-wrinkle) and dermatology (psoriasis, atopic dermatitis, squamous carcinoma)

FGK CLINICAL RESEARCH GMBH

Heimeranstrasse 35
80339 Munich - Germany
www.fgk-cro.de

MAIN CONTACT:

Dr. Edgar J. Fenzl, MD
Managing Director
edgar.fenzl@fgk-cro.de
Phone: + 49 (0) 89 893 119-22
Cell phone: + 49 (0) 172-673 8556

FGK Clinical Research GmbH is a Europe-based full service Contract Research Organization with offices in Germany (HQ), Poland, Czech Republic, Hungary and UK.

We provide full service for Phase II - IV clinical studies. FGK has experience in conducting multicountry, multicenter studies with hundreds of patients as well as single country studies with few patients. Regardless what size, we guarantee a personal service and work seamless with your team to provide an integrated solution committed to the success of the study.

With our over 100 highly qualified medical, scientific and regulatory experts, we have all the knowledge and experience necessary to succeed in global projects and can guide you through the clinical trial process, from planning and approval to the final report.

GAMS WELLNESS

P.O. Box 1119
94086 Bad Griesbach - Germany
www.gams-wellness.de

MAIN CONTACT:

Ms. Gabriela Gams
CEO
info@gamswellness.de
Phone: +49 8532 926552

Gams Wellness is based near Munich/ Bavaria. We are dealing with organic products for body care. The products are handmade in Germany, and of high quality. They can be used for Spa, Wellness and in shops. The scented massage candles are made of vegetable oils of natural resources in best quality. The facial and body treatment line and the bath confection are 100% organic.

We are organizing private label arrangement.



GENOWAY

181 Avenue Jean JAURES
69007 Lyon - France
www.genoway.com

MAIN CONTACT:

Mr. Kader Thiam
VP Transgenic Technologies
thiam@genoway.com
Phone: + 33 (0) 4 37 65 41 00

genOway designs and develops accurate *in vivo* and *in vitro* preclinical models for target validation, compound efficacy assessment and safety studies. In addition to providing highly advanced technological solutions for research models creation, we offer interactive scientific consulting at every step of the project, to enhance model quality, project de-risking, and better management of timelines.

By providing models to 14 of the Top 20 Pharma over the past sixteen years, the company has gathered an unparalleled experience and portfolio of exclusive technologies.

- genOway has created highly valuable models with impact on drug development programs. Our most recent models supported breakthroughs in immuno-oncology for targets such as OX40, CD137, CD40, PD1/PDL1, VISTA, ..., to: Investigate the mechanism underlying the immune checkpoint and its involvement in immune response escape during tumorigenesis
- Validate how blocking inhibitory molecules unleashes anti-tumor immunity, leading to long-lasting cancer regression in malignant tissues while displaying limited deleterious effect on normal ones
- Assess the efficacy, specificity, and safety of antibody-drug conjugates

We also provide access to more than 16,000 models of target validation (KO) among which some are already phenotyped, and ready to be analyzed.

We design and generate high quality *in vitro* and *in vivo* models by working closely with your scientists, to better understand the scientific needs underlying the model request: we offer in-depth analysis and interactive scientific consulting, before initiation and during development of the project. This process goes through face-to-face meetings in Japan to discuss the details of the model and to select jointly the best strategy. Such a customer oriented strategy with strong scientific input resulted in successful model generation for several Biopharmaceutical companies such as Astellas, Eisai, Ono Pharmaceutical, Takeda, Shionogi, etc. Finally, genOway guarantees its clients exclusive access to key technologies in the field and/or provides its clients with the ETO to all technologies and tools



INDICIA PRODUCTION

Za La Parliere
69610 Saint Genis L'Argentiere - France
www.indicia.fr

MAIN CONTACT:

Mr. Stéphane Legastelois
President
slegastelois@indicia.fr
Phone: +33 (0)4 74 72 36 10
Cell phone: +33 (0)6 80 75 89 46

Created in 2008, Indicia Production (CMO of 45 employees) offers industrial production services to Life Sciences companies wishing to outsource the formulation, filling and sterilization of liquid products and reagents.

Indicia has capabilities dedicated to the manufacturing of ready-to-use culture media and pharmaceutical sterile excipients.

Indicia also performs contract formulation and filling of sterile liquid Medical Devices (class I to III) and *in vitro* Diagnostic Medical Devices.

IRIS BIOTECH GMBH
Waldershofer Str. 49-51
95615 Marktredwitz - Germany
www.iris-biotech.de

MAIN CONTACT:
Dr. Thomas Bruckdorfer
CSO & VP Business Development
thomas.bruckdorfer@irisbiotech.de
Phone: +49 9231 9619 73

We carry over 6500 reagents for Drug Discovery, Drug Delivery, and Diagnostics and have specific know-how and production capabilities to supply from grams to multi-ton lots:

1. Sophisticated Starting Materials for Peptide Synthesis, Peptidomimetic and Medicinal Chemistry: Protected amino acids, coupling reagents, linkers and resins for solid phase organic and peptide chemistry.
2. Technologies for Polymer Therapeutics used in Combination Therapy and Personalized Medicine: PEGylating reagents and Poly(amino acids).
3. Reagents for Life Sciences and Diagnostics: Substrates, metabolites, glucuronides and inhibitors, inducers, antibody conjugates and cross-linkers.
4. Contract Manufacturing; our strong points are unusual derivatives with one or several chiral centers. We have unique possibilities to provide kg quantities of APIs on custom synthesis basis for very affordable conditions.

KLIFOVET AG
Geyersperger Str. 27
80689 Munich - Germany
www.klifovet.com

MAIN CONTACT:
Dr. Klaus Hellmann
Managing Director
klaus.hellmann@klifovet.com
Phone: +49 (0)89 5800820
Cell phone: +49 (0)171 7218954

Munich/ Germany-based KLIFOVET AG is the provider of high quality services for the Animal Health and Animal Nutrition Industry acting as a CRO, CMO and regulatory consultancy for the registration and marketing of all kind of veterinary medicinal products and feed additives. Klifovet has recently been awarded as the Best CRO by AnimalPharm.

Our services include:

- Project management and consultancy for the complete product development phase - from the idea to the marketed veterinary pharmaceutical or immunological product or feed additive/ feed
- Regulatory strategic consultancy, dossier writing, negotiations with the authorities
- CRO: Planning and conduct of veterinary clinical safety and efficacy
- studies in all target animal species (livestock and companion animals incl. aquaculture and bees)
- Full life cycle management incl. pharmacovigilance and QPPV services
- CMO support for EU QP release

We provide nearly 20 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout

Europe, North America and other continents. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA, FDA/USDA or other national standards.



LABORATORIOS RUBIÓ SA
C/ Indústria 29
Pol. Ind. Comte de Sert
08755 Castellbisbal
www.laboratoriosrubio.com

MAIN CONTACT:
Mr. Pelayo Rubió
General manager
prubio@labrubio.com
Mobile during the trip: +34 627439855

Rubió is a privately-owned Spanish Company devoted to the development, manufacturing and commercialization of products for specialist doctors, with a preferential focus on pharmaceutical products, and medical devices in CNS, muscular-skeletal, nephrology/urology and oncology /radiotherapy.

It has been a pioneer company in commercializing products for diseases of low incidence.

It is a leading company in attention deficit hyperactivity disorder in Spain and has a significant presence in rheumatoid arthritis, lupus and chronic kidney disease.



LABORATORIOS SALVAT SA
C/ Gall 30-36 08950 Barcelona
www.salvatbiotech.com

MAIN CONTACT:
Mr. Francesc Rosell
International Director
frosell@salvatbiotech.com
Phone: 671774333
Cell phone: 671774333

Spanish private group, devoted to the research, manufacture and marketing of pharmaceuticals. SALVAT products are marketed worldwide.

Areas of interest for out-licensing and in-licensing opportunities: gastroenterology, ENT, urology, pediatrics and ophthalmology.

SALVAT offer includes Contract Manufacturing and Product Development support through its Liquids Sterile (BFS) Production Plant, Research Center and proprietary technology platforms.

LEUKOCARE AG
Am Klopferspitz 19
82152 Martinsried/Munich - Germany
www.leukocare.com

MAIN CONTACT:
Dr. Roland Derwand, MBA
Vice President Scientific Medical Marketing & Sales
roland.derwand@leukocare.com
Phone: +49-(0)89-780 16 65 -22
Cell phone: +49-(0)162-183 49 60

LEUKOCARE provides a next-generation formulation technology platform for the protection of proteins like biopharmaceuticals to allow for the development of better products. Our patent protected Stabilizing and Protecting Solutions (SPS®) formulation technologies are offered for development projects of partners in the pharmaceutical and the medical device industry.

The SPS® platform is based on the following three main pillars: - improvement of thermal stability - protection during sterilization - functionalization of medical devices.

Our SPS® formulation technologies improve stability of biologics like antibodies, vaccines including live viral vectors, etc. in dry and liquid formulation including high-concentration antibody formulations. SPS® also protect proteins in combination medical devices like extracorporeal blood treatments, microneedles, wound dressings, etc. during sterilization and long term storage.

LEUKOCARE is a privately owned biotechnology company founded in 2003, and headquartered in Martinsried/Munich, Germany.

LEUKOS BIOTECH
C/ Muntaner 383, 3-2
08021 Barcelona
www.leukosbiotech.com

MAIN CONTACTS:
Mr. Enrique Llaudet / CEO
Ms. Ruth Muñoz / CSO
ellaudet@leukosbiotech.com
rmrisueno@leukosbiotech.com
Cell phone: + 34 634270335

Leukos Biotech is a biopharmaceutical company focused on the development of new treatments for Acute Myeloid Leukaemia and other haematological malignancies. The company was founded in 2015 as a spin-off from the Josep Carreras Leukaemia Research Institute (IJC).

Our main current project is the repurposing of a drug approved for the treatment of Parkinson as a new cure for Acute Myeloid Leukaemia.

MEDIGENE AG
Lochamer Str. 11
82152 Planegg/Martinsried - Germany
www.medigene.com

MAIN CONTACTS:
Dr. Rolf Kalhammer & Dr. Kerstin Pino-Tossi
business.development@medigene.com
Phone: +49 - 89 - 20 00 33 - 3306

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany.

Medigene concentrates on the development of personalized T cell-based immunotherapies. Therefore, the company is developing highly innovative complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development.

MIND THE BYTE SL
C/ Baldiri Reixac 4
08028 Barcelona
www.mindthebyte.com

MAIN CONTACT:
Mr. Alfons Nonell
CEO
alfons@mindthebyte.com
Cell phone: +34 644 121 180

Mind the Byte is a bioinformatics company located at Barcelona Science Park and specialized on computational drug discovery using Big Data and Machine learning approaches. Our software is sold through a pay-per-use SaaS platform (Software as a Service).

We work with over 30 biotechnology, pharmaceutical and veterinary companies as well as research centres and universities around the world to help them complete their R&D processes more quickly and economically. This means that we can get new medicines to patients faster.

With our SaaS platform, which we expand regularly with new programs and applications, researchers can easily predict biological activities, expand libraries (virtual screening), and understand why compounds work or how they bond with proteins, in addition to other applications. This helps cut the cost and time of the different phases of drug development. In developing the SaaS platform, we apply machine learning and big data techniques in order to speed up and improve the results and cut the time-to-market for new drugs.

We are Amazon Web Services technology partners.

NOVOTEC

11 rue Edison, Europarc du Chêne
F-69500 BRON - France
www.novotec-labs.com

MAIN CONTACT:

Prof. Daniel Hartmann
CSO
dhartmann@novotec-labs.com
Phone: 33 (0)4 78 61 46 31

Founded in 1997 by researchers of the Pasteur Institute of Lyon, the company offers you 35 years of experience in the extracellular matrix (structure, organization, function, remodeling...). Novotec carries out your studies in histology, immunohistochemistry, immunofluorescence, light and electron microscopy, image analysis and *in situ* hybridization. Novotec performed also customized studies completed by its R&D department (skin and cartilage engineering, fibrosis models...).

It produces and distributes also specific antibodies directed against the ECM macromolecules (collagens, elastin, fibronectin, matricryptins... from different species).

Because Novotec is particularly concerned about quality and client satisfaction, our Quality Management System is certified according to the ISO 9001: 2008 standard.

THERANEXUS

Pépinière Laennec, 60 avenue Rockefeller
69008 Lyon - France
www.theranexus.com

MAIN CONTACT:

Mr. Julien Veys
Chief Business Development Officer
julien.veys@theranexus.com
Phone: +33 1 46 54 85 57
Cell phone: +33 6 37 71 57 64

Theranexus is a privately-held, VC-backed, clinical-stage pharmaceutical company with headquarters in Lyon, France and created in 2013. The Company is a spin-off of France's Alternative Energies and Atomic Energy Commission (CEA).

Theranexus' science is based on the growing body of evidence of the key role of glial connexins in physiology and pathophysiology of the CNS. Indeed, glial connexins are the key to the instrumental role of glial cells network in supporting synaptic activity and plasticity. As a result Theranexus' scientists have evidenced that by combining a CNS drug targeting the synaptic transmission together with the right connexin modulator, this allows to generate a new pharmacological profile with a higher efficacy of the CNS drug. Based on this science, Theranexus' team first identify marketed CNS drugs of interest in underserved indications with large market potential, and then tests various combinations with a library of off-patent drugs, repositioned as connexin modulators, in relevant models of the disease. By leveraging on the extensive knowledge available about the two drugs used in the combination, Theranexus' drug candidates could therefore benefit from expedited regulatory pathways with reduced development costs.

Theranexus currently has 3 products in clinical development: THN102 (phase 2) a combination having achieved proof of concept in man and developed for the treatment of Excessive Daytime Sleepiness associated with narcolepsy and Parkinson's disease, THN101 (regulatory preclinical development) for the treatment of neuropathic pain and THN201 (preclinical development) for the treatment of Alzheimer's disease associated dementia.



THROMBOTARGETS

THROMBOTARGETS EUROPE SL

Av/ Canal Olímpic s/n, Edif 86, 2a PI
08860 Castelldefels
www.thrombotargets.com

MAIN CONTACT:

Mr. Ignasi Miquel
Strategic Alliances, Director
ignasimiquel@thrombotargets.com
Cell phone Mobile during the trip: + 34 656875160

Thrombotargets Europe is a biotech Company based in Barcelona, Spain, incepted in 2005. It has HeadQuarters and Laboratories at the Mediterranean Technology Park (Castelldefels-Barcelona) and at the National Center of Biotechnology (Madrid).

Thrombotargets Europe's leading product, TT-173 topical hemostat for surgical bleeding, has finished a successful Phase I in dental extraction, and Phase 11 Clinical Trial in Skin Graft. A sequential adaptative Phase 11/111 on is TKA ongoing. TT-173 is a human recombinant Tissue Factor(rhTF)-based topical hemostat that is being developed as an adjunct to arrest bleeding in surgical procedures . Tissue Factor is the protein triggering the coagulation cascade. Thrombotargets is also developing hemostatic medical devices, and other programs in the blood-related field (anticoagulation, antifibrinolysis ...).

Thrombotargets is looking for potential Licensees for its TT-173 topical hemostat.

ZeClinics
Drug Discovery Through Zebrafish

ZECLINICS, SL

C/ Sant Pau 113, 4-1
08001 Barcelona
www.zeclinics.com


MAIN CONTACT:

Mr. Davide D'Amico
CEO
davide.damico@zeclinics.com
Cell phone: +34 654 026 736

ZeClinics is a Contract Research Organization (CRO) and early-phase biopharmaceutical company (PHARMA) using zebrafish for drug discovery and biomedical research. Our track records with pharma leaders, biotech and academic centers and more than 25.000 scientific publications guarantee that using zebrafish in preclinical early phases could save up to 10X time and budget in R&D with a 95% predictivity on the effect of new drugs in humans.

ZeClinics strength lies on our extensive experience on zebrafish research and our permanent collaboration with academics, imaging processing experts and other biotech/pharma, which allow us to perform and improve high- throughput assays to test the safety of chemical compounds with pharmaceutical, cosmetic or nutritional potential. We also count with a growing portfolio of efficacy assays to test the biomedical relevance of novel compounds in the fields of oncology and neural disorders through zebrafish. However, our main value is the ability to listen clients' requirements and develop custom phenotypical assays with zebrafish to test the impact of new compounds in other biomedical topics such as metabolism, anti-microbiology or other diseases.

We offer three main areas of services: i) ZeTox, combining acute, chronic, general and organ-specific toxicology test; ii) ZeGenesis, a platform exploiting the license of use of CR1SPR/Cas9 for generation of knock-out, knock-in, transgenics zebrafish or cell lines; iii) ZeEfficacy to evaluate early the efficacy of libraries of compounds with highcontent phenotypical screenings in healthy or disease model zebrafish lines.



Partners:



This initiative is part of the project bioXclusters plus – the European Strategic Cluster Partnership (ESCP) on Personalised Healthcare which has received funding from the European Union's COSME Programme (2014-2020)

